Origin of delayed development of drug metabolism in the newborn rat

Effects in Rats of Maternal Exposure to Raspberry Leaf and Its Constituents on the Activity of Cytochrome P450 Enzymes in the Offspring

The goal of our study was to determine whether maternal exposure to red raspberry leaf (RRL) and its constituents can permanently alter biotransformation of fluorogenic substrates by cytochrome P450 (CYP) in the livers of male and female offspring. Nulliparous female rats received vehicle, raspberry leaf, kaempferol, quercetin, or ellagic acid orally once breeding had been confirmed until parturition. Hepatic microsomes were prepared from animals at birth (postnatal day 1 [PND1]), weaning (PND21), PND65, and PND120 to determine the biotransformation of 8 fluorogenic substrates. The pattern of biotransformation of all but 2 of the substrates was gender specific. Maternal consumption of RRL increased biotransformation of 3 substrates by female offspring at PND120 resulting in a more masculine profile. Kaempferol and quercetin had a similar effect to RRL. These results suggest that maternal consumption of either RRL or some of its constituents leads to long-term alterations of CYP activity in female offspring.

Gene expression profiles of drug-metabolizing enzymes (DMEs) in rat liver during pregnancy and lactation

A cDNA microarray analysis was conducted to examine hepatic gene expression profiles in pregnant and lactating F344 rats compared to a virgin control group using an Affymetrix GeneChip system. Of the approximately 16000 gene transcripts interrogated, more than 1000 were significantly modified in their expression when detected either in late pregnancy (19 days of gestation, GD 19, 513 genes upregulated and 579 downregulated) or on the day of delivery (postpartum 0 day, PPD 0, 497 upregulated and 733 downregulated). Particular interest was paid to the gene expression of drug-metabolizing enzymes (DMEs) and nuclear receptors (NRs). Though the expression of a few genes, those for CYP7A1, CYP51 and Sultx3, increased, the expression of a number of genes encoding DMEs (Phase I and Phase II) and NRs decreased during pregnancy and lactation. Changes in the expression of 9 genes encoding DMEs and NRs were confirmed by quantitative real-time PCR. For all 9 genes tested, overall, the results of the microarray and real-time PCR analyses were in agreement. This is the first application of a microarray analysis to the expression profiling of genes encoding DMEs and NRs in the liver of pregnant and lactating rats. When combined with other studies, the present study may provide a basis for investigating the mechanism of toxicity of environmental or other nonphysiologic chemicals to the fetus and mother and drug safety during pregnancy and lactation.

Changes in cytochrome P450 isozymes (CYPs) protein levels during lactation in rat liver

The effects of pregnancy on CYPs protein level in the liver have been investigated in our previous study. Since pregnancy was associated with a decrease in CYPs protein level, the objective of this study was to investigate whether CYPs protein can revert to the virgin control level after delivery. Western blot analysis was performed to investigate the changes of total nine CYPs protein (CYP1A1, CYP2B1/CYP2B2, CYP2C6, CYP2C12, CYP2D1, CYP2D4, CYP2E1, CYP3A1 and CYP4A1) at three distinct phases: delivery (postpartum day 0, PPD 0), peak lactation (PPD 14) and on weaning (PPD 28). By PPD 0, CYP1A1, 2B1, 2B2, 2C6, 2E1 and CYP4A1 were markedly down-regulated when compared with virgin controls. By PPD 14, however, CYP1A1, 2B1, 2B2 and CYP2C6 returned to the virgin control level. All the decreased CYPs during lactation were at the virgin control level at PPD 28. The expression of CYP2C12, CYP2D1 and CYP 3A1 did not differ between lactating, post-lactation and virgin control rats. CYP2D4 was not detectable in microsomal proteins obtained from virgin control rats at a protein loading of 20 mug total protein per lane.

Effects of pregnancy on CYPs protein expression in rat liver

A body of evidence suggests that pregnancy may be responsible for the depression in the microsomal enzyme activity and the reduction in the total content of cytochrome P450 (CYP) in the rat liver. However, changes in expression of individual CYP isozyme remain poorly known. The current study was designed to examine the changes in CYPs protein expression in the liver of F344 rats in midpregnancy and late pregnancy by Western blot analysis and immunohistochemistry. Total nine antirat CYPs antibodies (CYP1A1, CYP2B1/CYP2B2, CYP2C6, CYP2C12, CYP2D1, CYP2D4, CYP2E1, CYP3A1, and CYP4A1) were used. In comparison with age-matched nonpregnant control rats, there were significant decreases in hepatic levels of CYP2B2, CYP2C6, and CYP4A1 in midpregnancy (day 13) and CYP2B2, CYP2C6, CYP4A1, CYP1A1, CYP2B1, and CYP2E1 in late pregnancy (day 19). The expression of CYP2C12, CYP2D1, and CYP 3A1 did not differ between nonpregnant and pregnant rats, and CYP2D4 was not detectable in microsomal proteins obtained from nonpregnant and pregnant rats at a protein loading of 20 mug total protein per lane. Immunohistochemistry showed that there were no differences in the distribution and degree of immunostainability for the abovementioned antibodies to nine CYPs between pregnant and nonpregnant rats.

Expression of P450 isoenzymes during rat liver organogenesis

1. The expression of P450 isoenzymes in foetal and neonatal hepatic microsomes was determined by measuring the metabolism of marker substrates and by studying the expression of P450 isoenzymes at the protein and mRNA level. 2. Monooxygenase activities were not measurable at day 10 of gestation, but shortly before birth (day 20 of gestation) and thereafter a surge in monooxygenase activities was observed using ethoxyresorufin, aniline, nitroanisole, aminopyrine, dimethylnitrosamine and aldrin as substrates. 3. In contrast, as early as day 10 of gestation, post oxidative drug metabolism was measurable, when assessed for reactions catalysed by UDP-glucuronyltransferase, glutathione S-transferase and epoxide hydrolase. 4. Microsomal proteins isolated from foetal/perinatal rats did not crossreact with antibodies raised to CYP1A1, CYP1A2, CYP2A1, CYP2B1, CYP2E1, CYP3A1 and CYP4A1 at a protein loading of 3 micrograms total protein/well. 5. With the exception of CYP2E1 mRNA and CYP4A1 mRNA there was little evidence to suggest the expression of CYP1A1, CYP1A2 and CYP2A1 mRNA. 6. The mRNA of CYP2B1, CYP2C7 and CYP3A1 was not detectable in foetal/perinatal rat liver extracts at a loading rate of 10 micrograms total RNA. 7. Microsomal proteins isolated from neonatal rats crossreacted with antibodies raised to CYP2C6, CYP2E1, CYP3A1 and CYP4A1, albeit at varying intensities. 8. Concomitantly, CYP2A1, CYP2E1 and CYP4A1 mRNA transcripts were detectable in Northern blot hybridization experiments using neonatal rat liver RNA extracts.

Effects of the interferon inducing agents tilorone and polyriboinosinic acid . polyribocytidylic acid (poly IC) on the hepatic monooxygenase systems of pregnant and fetal rats

Interferon inducing agents, including tilorone and polyriboinosinic acid . polyribocytidylic acid (poly IC), are known to depress hepatic cytochrome P-450-dependent monooxygenase systems and the induction of these systems by phenobarbital (PB) and 3-methylcholanthrene (MC) in mature male rats. The current study investigated the effects of tilorone and poly IC on the cytochrome P-450 systems of non-induced, PB-induced, MC-induced and pregnenolonecarbonitrile (PCN)-induced pregnant rats and their fetuses. Pregnant rats received either tilorone or poly IC and saline, PB, MC or PCN, and microsomes from their livers and those of their fetuses were examined for cytochrome P-450 content, aminopyrine (AP) N-demethylase activity and benzo[a]pyrene (BP) hydroxylase activity. The generalization can be made from these studies that, when the interferon inducing agents caused changes in cytochrome P-450 content or monooxygenase activities of either induced (PB, MC or PCN) or non-induced (saline) animals, decreases were seen in maternal livers and increases in fetal livers. Thus, in maternal livers tilorone depressed cytochrome P-450 and AP N-demethylase activity in non-induced and PB-, MC- and PCN-induced rats and BP hydroxylase activity in the induced animals; BP hydroxylase activity was not depressed in non-induced maternal livers. Poly IC depressed cytochrome P-450 and AP N-demethylase activity in non-induced and PB-induced rats but not in PCN-induced animals. BP hydroxylase was depressed by poly IC in both PB- and PCN-induced animals. Fetal hepatic cytochrome P-450 and monooxygenase activities were increased by tilorone in PB- and PCN-induced rats but not in non-induced or MC-induced animals. Poly IC increased cytochrome P-450 and both monooxygenase activities in PB- and PCN-induced fetal livers, whereas only BP hydroxylase activity was increased in the fetuses of non-induced rats. Several possible explanations are offered for the opposite effects produced by interferon inducing agents in maternal and fetal livers. Unlike maternally administered tilorone, which induced fetal cytochrome P-450 and monooxygenase activities in the liver, intrauterine tilorone depressed cytochrome P-450 and had no effect on AP N-demethylase or BP hydroxylase activities in the fetal liver. Intrauterine poly IC was without effect on the cytochrome P-450 systems of the fetal liver. Treatment of pregnant rats with tilorone on days 17-20 of gestation inhibited normal maternal weight gain and produced overt signs of toxicity.(ABSTRACT TRUNCATED AT 400 WORDS)

Hepatic drug metabolism in pregnancy

The results of both isolated tissue and whole animal experimentation, whilst showing some unexplored inconsistencies, suggest that late pregnancy is associated with a reduced ability of the liver to metabolise foreign compounds. The mechanism of this reduced capacity and the physiological reason for it are unclear but such change does have implication for therapeutic response in pregnancy. Available results from the limited and often poorly structured studies of drug levels in pregnant women neither prove nor disprove the existence of similar changes in hepatic monooxygenase activity during human pregnancy.

Influence of sex and oral contraceptive steroids on paracetamol metabolism

Paracetamol metabolism was investigated in eight healthy males, eight healthy females and eight healthy females receiving oral contraceptive steroids (OCS). Paracetamol clearance was 22% greater in males compared to the control female group. This difference was entirely due to increased activity of the glucuronidation pathway in males, there being no sex-related differences in the sulphation or oxidative metabolism of paracetamol. Paracetamol clearance in females using OCS was 49% greater than in the control females. Glucuronidation and oxidative metabolism were both induced in OCS users (by 78% and 36% respectively) but sulphation was not altered. Although sex-related differences in paracetamol metabolism are unlikely to be of clinical importance, induction of paracetamol metabolism by OCS may have clinical and toxicological consequences.

Comparison of the effects of N-nitrosodimethylamine on pregnant and nonpregnant Holtzman rats

Single oral doses of N-nitrosodimethylamine or olive oil were given to nonpregnant and pregnant female Holtzman rats on different days of pregnancy (days 7-18, where day 0 was considered to be the sperm positive day). Serological and histopathological studies were performed on animals killed 2 days after treatment. In comparison with the values obtained in nonpregnant controls, the following parameters in pregnant controls were significantly increased: relative liver weights (days 9-20), liver ascorbic acid concentrations (day 12), blood urea nitrogen (days 16-20), serum triglyceride (days 14-20), serum inorganic phosphorus (days 12-18), and serum glutamic-pyruvic transaminase (days 14-20). The following parameters were decreased in pregnant rats compared with nonpregnant controls: relative organ weights (kidneys, adrenals and thyroids), serum glucose (days 12-20), total serum protein (days 9 and 16-20), and serum alkaline phosphatase (day 20). The serum cholesterol levels in pregnant rats were significantly decreased on days 9-15 of pregnancy and significantly increased on day 20. The numbers of mitotic cells in the livers of pregnant rats were greatly increased compared with nonpregnant rats on all days of pregnancy, while the adrenal cortex contained a significantly higher number of mitotic cells only on days 16 and 18. Compared with control values, NDMA given orally (15 or 20 mg/kg body weight) increased the following in both pregnant and nonpregnant rats: numbers of mitotic cells in the liver and adrenal cortex, relative adrenal weights, serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase. NDMA treatment decreased liver ascorbic acid and total serum protein in both pregnant and nonpregnant rats. In nonpregnant rats NDMA also increased relative liver weights (not significant) and serum alkaline phosphatase levels. NDMA increased serum alpha-hydroxybutyric dehydrogenase in pregnant rats on day 20 and decreased foetal weights (in rats treated on days 13 and 18). NDMA treatment was not lethal to nonpregnant rats or to pregnant rats up to day 16 of pregnancy, but single oral doses of 15 and 20 mg NDMA/kg killed 9.4 and 35.3%, respectively, of rats treated on day 18 of pregnancy. In general, the acute toxic effect of NDMA, as measured by changes in the above parameters, was greater in pregnant than in nonpregnant rats, especially near the end of pregnancy.

Hepatic microsomal drug metabolism in the pregnant rat

1. Hepatic microsomal drug metabolism determined with the substrates aniline (p-hydroxylation), ethylmorphine (N-demethylation) and p-nitrobenzoic acid (reduction), decreased during gestation in the rat to 53-73% of non-pregnant control levels by day 20 of gestation. 2. Enzyme activity remained low at one day post-partum, but had returned to control non-pregnant levels by five days post-partum. 3. The total capacity of the liver to metabolize drugs remained unchanged or increased because liver weight was increased by up to 40% during pregnancy. 4. Changes in drug metabolism were not related to alterations in the concentration, substrate-induced binding affinity (Ks) or maximal spectral change (delta Amax) of cytochrome P-450. 5. Alterations in hepatic drug metabolism are possibly mediated via changes in microsomal phospholipids and/or the cytochrome P-450 spin-state equilibrium as as pregnancy was associated with a decrease in (a) microsomal total phospholipids, (b) the phosphatidylcholine to phosphatidylethanolamine ratio and (c) the high-spin form of ferricytochrome P-450.

Modification of the mutagenicity and teratogenicity of cyclophosphamide in rats with inducers of the cytochromes P-450

Cyclophosphamide must be enzymatically activated to be either mutagenic or teratogenic. This activation is thought to be catalyzed by the cytochrome P-450 monooxygenase system. To study the relationship between the mutagenic and teratogenic metabolites of cyclophosphamide, the mutagenicity and teratogenicity of this drug were compared after activation by rats pretreated with chemicals (phenobarbital and beta-naphthoflavone) inducing different cytochromes P-450. Activation of cyclophosphamide to mutagenic metabolites by enzyme fractions from rats on day 13 of gestation was measured with the Ames test using Salmonella typhimurium TA1535. Teratogenicity was assessed in vivo by treatment of rats with cyclophosphamide on day 13 of gestation. Cyclophosphamide was activated to mutagenic metabolites to the same extent (on a tissue wet weight basis) by enzyme fractions from maternal liver, kidney and placenta, despite differences in cytochrome P-450 content. Fetal homogenates did not activate cyclophosphamide. Phenobarbital pretreatment increased the activation of cyclophosphamide to mutagenic metabolites by maternal liver microsomes 10-fold and liver cytochrome P-450 content 1.8 fold; however, this drug did not alter the activation of cyclophosphamide by maternal kidney, by placenta or by the fetus. Phenobarbital pretreatment increased the teratogenicity of cyclophosphamide in rats on day 13 of gestation (increased incidence of malformed embryos, decreased fetal weight). Pretreatment with beta-naphthoflavone did not induce liver cytochrome P-450 in the pregnant rat and did not change the activation of cyclophosphamide to mutagenic metabolites by liver, kidney, placenta or the fetus. Pretreatment with this polycyclic aromatic hydrocarbon had no effect or decreased the teratogenicity of cyclophosphamide. Thus, these experiments suggest that the mother, rather than the fetus, is the site of activation of cyclophosphamide; after phenobarbital pretreatment the predominant site of cyclophosphamide activation is the maternal liver. There appears to be a correlation between the teratogenicity and mutagenicity of cyclophosphamide after induction of the cytochromes P-450. We can speculate that the "proximate teratogen" of cyclophosphamide may also be the "proximate mutagen".

Reproduction and growth of progeny of female mice mated after treatment with crufomate

Effects on reproduction and litter growth were studied for two successive reproductive periods (RP)--interval between caging females with males and whelping--in female mice treated dermally with crufomate at 100 or 50 mg/kg on days 35 and 21 before caging with untreated males. Each treatment with crufomate caused about 50% reversible inhibition of cholinesterase activity without inducing any signs of toxicity. The higher dose reduced the conception rate and the number of litters and young born and weaned during the two RPs. It also reduced the lactation index, weaning weight of males and females, and mature weight of males in the first litter. The lower dose prolonged the gestation period and reduced the lactation index and the number of litters and young weaned in the first RP and conception rate and number of litters and young born and weaned in the second RP. The lower dose reduced the weaning and mature weights of the first litter and mature weight of males in the second litter. The higher dose reduced the body weight and the lower dose increased the adrenal weight of the treated females.

Developmental aspects of hepatic glutathione S-transferase activities in male rats

The postnatal development of glutathione S-transferase activities was investigated in post-microsomal supernatants of the livers of male rats. A period of up to the age of 200 days was covered, using styrene 7,8-oxide as the electrophilic substrate for the transferase. Activity in animals on the day of delivery was small but significantly above the level of spontaneous conjugation. During 5 weeks postpartum the specific activity increased regularly to about sixfold when expressed as per mg of cytosolic protein, thereafter the activity slightly decreased. During the 5th postnatal week a sudden decrease in activity was observed, but it returned to the original value within about 5 days. The effect of weaning on this phenomenon was studied by comparing weaned with non-weaned rats in an investigation of glutathione S-transferase maturation in the 4th and 5th week postpartum, using styrene 7,8-oxide and 1-chloro-2,4-dinitrobenzene as the electrophilic substrates. Weaned rats exhibited the decrease in activity only when styrene oxide was the substrate. It is concluded that glutathione S-transferase levels in rat liver are low at birth, and develop gradually during the first 5 postnatal weeks. Transferase activities towards styrene oxide and chlorodinitrobenzene appears to mature independently and are partly associated with weaning.

Pharmacokinetics of clorazepate in pregnant and non-pregnant women

A single dose of clorazepate 20 mg was injected i.m. in 7 pregnant and 7 non-pregnant women. Blood samples were collected for one week, and urine was collected for 24 h after the dose. The concentrations of clorazepate and its metabolite nordiazepam were determined by electron capture gas liquid chromatography. There was no difference between the two groups on physical examinations. Clorazepate was rapidly absorbed and the peak concentration was reached within 2 h. Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women. Nordiazepam reached its peak concentration within 12 h after dosing; its mean half life of elimination was 180 h in pregnant women and 60 h in non-pregnant women. Within 24 h, 1.3% of the clorazepate was recovered in urine from pregnant women and 7% in urine from the non-pregnant women.